Elevated levels of vascular endothelial growth factor in the sera of patients with rheumatoid arthritis - Correlation with disease activity

被引:96
作者
Sone, H
Sakauchi, M
Takahashi, A
Suzuki, H
Inoue, N
Iida, K
Shimano, H
Toyoshima, H
Kawakami, Y
Okuda, Y
Matsuo, K
Yamada, N
机构
[1] Univ Tsukuba, Inst Clin Med, Dept Internal Med, Tsukuba, Ibaraki 3058575, Japan
[2] Univ Tsukuba, Inst Clin Med, Dept Lab Med, Tsukuba, Ibaraki 3058575, Japan
[3] Mito Red Cross Hosp, Dept Med 3, Ibaraki, Osaka, Japan
[4] Toagosei Co Ltd, Tsukuba Res Lab, Biosci Res Dept, Tsukuba, Ibaraki, Japan
基金
日本学术振兴会;
关键词
vascular endothelial growth factor (VEGF); vascular permeability factor (VPF); rheumatoid arthritis; disease activity; clinical studies;
D O I
10.1016/S0024-3205(01)01264-4
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 [基础医学];
摘要
To evaluate vascular endothelial growth factor (VEGF) levels in relation to disease activity in rheumatoid arthritis (RA), VEGF in the serum of 155 patients with RA and 75 healthy control subjects was quantified by our highly sensitive enzyme-linked immunosorbent assay. VEGF levels were found to correlate with the articular index (AI) and Lansbury's activity index (LI). Patients with RA had a mean serum VEGF concentration of 153.5 +/- 111.8 pg/ml, which was significantly higher than control subjects (104.8 +/- 65.7 pg/ml; P<0.01). VEGF concentration was elevated significantly according to disease progression as expressed by stages I to IV and correlated with AI (r=0.530, P<0.0001) and LI (r=0.688, P<0.0001) in stages I and II as well as with the conventional erythrocyte sedimentation rate or serum C-reactive protein concentration. Serum VEGF levels may therefore be valuable as a marker of disease activity in patients with early RA, and this cytokine may play a significant role in the pathophysiology of RA. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:1861 / 1869
页数:9
相关论文
共 18 条
[1]
Amoroso A, 1997, Eur Rev Med Pharmacol Sci, V1, P17
[2]
THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[3]
EASTGATE JA, 1988, LANCET, V2, P706
[4]
VASCULAR-PERMEABILITY FACTOR ENDOTHELIAL GROWTH-FACTOR (VPF/VEGF) - ACCUMULATION AND EXPRESSION IN HUMAN SYNOVIAL-FLUIDS AND RHEUMATOID SYNOVIAL TISSUE [J].
FAVA, RA ;
OLSEN, NJ ;
SPENCERGREEN, G ;
YEO, KT ;
YEO, TK ;
BERSE, B ;
JACKMAN, RW ;
SENGER, DR ;
DVORAK, HF ;
BROWN, LF .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (01) :341-346
[5]
MOLECULAR AND BIOLOGICAL PROPERTIES OF THE VASCULAR ENDOTHELIAL GROWTH-FACTOR FAMILY OF PROTEINS [J].
FERRARA, N ;
HOUCK, K ;
JAKEMAN, L ;
LEUNG, DW .
ENDOCRINE REVIEWS, 1992, 13 (01) :18-32
[6]
Harada M, 1998, SCAND J RHEUMATOL, V27, P377
[7]
Ikeda M, 2000, J PATHOL, V191, P426
[8]
Expression of vascular endothelial growth factor by synovial fluid neutrophils in rheumatoid arthritis (RA) [J].
Kasama, T ;
Kobayashi, K ;
Yajima, N ;
Shiozawa, F ;
Yoda, Y ;
Takeuchi, HT ;
Mori, Y ;
Negishi, M ;
Ide, H ;
Adachi, M .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2000, 121 (03) :533-538
[9]
Kikuchi K, 1998, BRIT J DERMATOL, V139, P1049
[10]
KOCH AE, 1994, J IMMUNOL, V152, P4149